{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:41:20Z","timestamp":1794008480485,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alkermes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1038\/s41380-018-0284-1","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T11:42:41Z","timestamp":1540813361000},"page":"1580-1591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Opioid system modulation with buprenorphine\/samidorphan combination for major depressive disorder: two randomized controlled studies"],"prefix":"10.1038","volume":"25","author":[{"given":"Maurizio","family":"Fava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Thase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-1110","authenticated-orcid":false,"given":"Madhukar H.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Ehrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asli","family":"Memisoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narinder","family":"Nangia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle D.","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"key":"284_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000448661","volume":"86","author":"RJ Baldessarini","year":"2017","unstructured":"Baldessarini RJ, Forte A, Selle V, Sim K, Tondo L, Undurraga J, et al. Morbidity in depressive disorders. Psychother Psychosom. 2017;86:65\u201372.","journal-title":"Psychother Psychosom"},{"key":"284_CR2","doi-asserted-by":"publisher","first-page":"e1001547","DOI":"10.1371\/journal.pmed.1001547","volume":"10","author":"AJ Ferrari","year":"2013","unstructured":"Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10:e1001547.","journal-title":"PLoS Med"},{"key":"284_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/15622970701227829","volume":"8","author":"M Bauer","year":"2007","unstructured":"Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 2007;8:67\u2013104.","journal-title":"World J Biol Psychiatry"},{"key":"284_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pneurobio.2015.12.001","volume":"152","author":"R Machado-Vieira","year":"2017","unstructured":"Machado-Vieira R, Henter ID, Zarate CA Jr. New targets for rapid antidepressant action. Prog Neurobiol. 2017;152:21\u201337.","journal-title":"Prog Neurobiol"},{"key":"284_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4088\/JCP.8133su1c.03","volume":"70","author":"GI Papakostas","year":"2009","unstructured":"Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009;70 (suppl 6):16\u201325.","journal-title":"J Clin Psychiatry"},{"key":"284_CR6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1176\/ajp.2006.163.7.1161","volume":"163","author":"M Fava","year":"2006","unstructured":"Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163:1161\u201372.","journal-title":"Am J Psychiatry"},{"key":"284_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0193-953X(05)70283-5","volume":"19","author":"M Fava","year":"1996","unstructured":"Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19:179\u2013200.","journal-title":"Psychiatr Clin North Am"},{"key":"284_CR8","doi-asserted-by":"publisher","first-page":"16065","DOI":"10.1038\/nrdp.2016.65","volume":"2","author":"C Otte","year":"2016","unstructured":"Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive disorder. Nat Rev Dis Prim. 2016;2:16065.","journal-title":"Nat Rev Dis Prim"},{"key":"284_CR9","first-page":"4","volume":"1","author":"W Li","year":"2016","unstructured":"Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013;10:e1001403.\u00a0","journal-title":"Transl Perioper Pain Med"},{"key":"284_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s13311-017-0527-x","volume":"14","author":"MH Han","year":"2017","unstructured":"Han MH, Nestler EJ. Neural substrates of depression and resilience. Neurotherapeutics. 2017;14:677\u201386.","journal-title":"Neurotherapeutics"},{"key":"284_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3758\/s13415-014-0323-6","volume":"15","author":"NP Jones","year":"2015","unstructured":"Jones NP, Siegle GJ, Mandell D. Motivational and emotional influences on cognitive control in depression: a pupillometry study. Cogn Affect Behav Neurosci. 2015;15:263\u201375.","journal-title":"Cogn Affect Behav Neurosci"},{"key":"284_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1017\/S0033291707002206","volume":"38","author":"A Scheurich","year":"2008","unstructured":"Scheurich A, Fellgiebel A, Schermuly I, Bauer S, Wolfges R, Muller MJ. Experimental evidence for a motivational origin of cognitive impairment in major depression. Psychol Med. 2008;38:237\u201346.","journal-title":"Psychol Med"},{"key":"284_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.neubiorev.2016.07.002","volume":"69","author":"A Kupferberg","year":"2016","unstructured":"Kupferberg A, Bicks L, Hasler G. Social functioning in major depressive disorder. Neurosci Biobehav Rev. 2016;69:313\u201332.","journal-title":"Neurosci Biobehav Rev"},{"key":"284_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1176\/appi.ajp.2015.15070921","volume":"173","author":"M Fava","year":"2016","unstructured":"Fava M, Memisoglu A, Thase ME, Bodkin JA, Trivedi MH, de Somer M, et al. Opioid modulation with buprenorphine\/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial. Am J Psychiatry. 2016;173:499\u2013508.","journal-title":"Am J Psychiatry"},{"key":"284_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/mp.2014.185","volume":"20","author":"DT Hsu","year":"2015","unstructured":"Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Walker SJ, et al. It still hurts: Altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder. Mol Psychiatry. 2015;20:193\u2013200.","journal-title":"Mol Psychiatry"},{"key":"284_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/npp.2017.200","volume":"43","author":"L Nummenmaa","year":"2018","unstructured":"Nummenmaa L, Karjalainen T. Opioidergic regulation of pain and pleasure in human social relationships. Neuropsychopharmacology. 2018;43:217\u20138.","journal-title":"Neuropsychopharmacology"},{"key":"284_CR17","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1111\/bph.13812","volume":"175","author":"L Nummenmaa","year":"2018","unstructured":"Nummenmaa L, Tuominen L. Opioid system and human emotions. Br J Pharmacol. 2018;175:2737\u201349.","journal-title":"Br J Pharmacol"},{"key":"284_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.physbeh.2013.04.009","volume":"122","author":"P B\u00e9rub\u00e9","year":"2013","unstructured":"B\u00e9rub\u00e9 P, Laforest S, Bhatnagar S, Drolet G. Enkephalin and dynorphin mRNA expression are associated with resilience or vulnerability to chronic social defeat stress. Physiol Behav. 2013;122:237\u201345.","journal-title":"Physiol Behav"},{"key":"284_CR19","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1001\/archpsyc.63.11.1199","volume":"63","author":"SE Kennedy","year":"2006","unstructured":"Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63:1199\u2013208.","journal-title":"Arch Gen Psychiatry"},{"key":"284_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.brainres.2009.09.074","volume":"1314","author":"AT Knoll","year":"2010","unstructured":"Knoll AT, Carlezon WA Jr. Dynorphin, stress, and depression. Brain Res. 2010;1314:56\u201373.","journal-title":"Brain Res"},{"key":"284_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","volume":"15","author":"JA Bodkin","year":"1995","unstructured":"Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15:49\u201357.","journal-title":"J Clin Psychopharmacol"},{"key":"284_CR22","doi-asserted-by":"publisher","first-page":"e785","DOI":"10.4088\/JCP.13m08725","volume":"75","author":"JF Karp","year":"2014","unstructured":"Karp JF, Butters MA, Begley AE, Miller MD, Lenze EJ, Blumberger DM, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75:e785\u201393.","journal-title":"J Clin Psychiatry"},{"key":"284_CR23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(82)90727-9","volume":"2","author":"HM Emrich","year":"1982","unstructured":"Emrich HM, Vogt P, Herz A, Kissling W. Antidepressant effects of buprenorphine. Lancet. 1982;2:709.","journal-title":"Lancet"},{"key":"284_CR24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/JCP.0b013e31818638a4","volume":"28","author":"PW Nyhuis","year":"2008","unstructured":"Nyhuis PW, Gastpar M, Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol. 2008;28:593\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"284_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1176\/appi.ajp.2015.15040535","volume":"173","author":"Y Yovell","year":"2016","unstructured":"Yovell Y, Bar G, Mashiah M, Baruch Y, Briskman I, Asherov J, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016;173:491\u20138.","journal-title":"Am J Psychiatry"},{"key":"284_CR26","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/npp.2014.330","volume":"40","author":"E Ehrich","year":"2015","unstructured":"Ehrich E, Turncliff R, Du Y, Leigh-Pemberton R, Fernandez E, Jones R, et al. Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology. 2015;40:1448\u201355.","journal-title":"Neuropsychopharmacology"},{"key":"284_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejpain.2008.04.011","volume":"13","author":"HG Kress","year":"2009","unstructured":"Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009;13:219\u201330.","journal-title":"Eur J Pain"},{"key":"284_CR28","doi-asserted-by":"crossref","unstructured":"Bidlack JM, Knapp BI, Deaver D, Plotnikava M, Arnelle D, Quinn AM et al. ALKS 5461: affinity, potency, and functional activity of buprenorphine and samidorphan alone and in combination [poster]. 73rd Annual Meeting of the Society of Biological Psychiatry, New York, NY; May 10\u201312, 2018.","DOI":"10.1016\/j.biopsych.2018.02.1057"},{"key":"284_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/wps.20421","volume":"16","author":"A Khan","year":"2017","unstructured":"Khan A, Fahl Mar K, Faucett J, Khan Schilling S, Brown WA. Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013. World Psychiatry. 2017;16:181\u201392.","journal-title":"World Psychiatry"},{"key":"284_CR30","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","volume":"287","author":"BT Walsh","year":"2002","unstructured":"Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. J Am Med Assoc. 2002;287:1840\u20137.","journal-title":"J Am Med Assoc"},{"key":"284_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1755-5949.2009.00102.x","volume":"16","author":"GM Chandler","year":"2010","unstructured":"Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M. RESEARCH: validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16:322\u20135.","journal-title":"CNS Neurosci Ther"},{"key":"284_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000457131","volume":"86","author":"N Timmerby","year":"2017","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Psychother Psychosom"},{"key":"284_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000457131","volume":"86","author":"N Timmerby","year":"2017","unstructured":"Timmerby N, Andersen JH, Sondergaard S, Ostergaard SD, Bech P. A systematic review of the clinimetric properties of the 6-item version of the Hamilton Depression Rating Scale (HAM-D6). Psychother Psychosom. 2017;86:141\u20139.","journal-title":"Psychother Psychosom"},{"key":"284_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50\u20135.","journal-title":"Br J Med Psychol"},{"key":"284_CR35","doi-asserted-by":"publisher","first-page":"464","DOI":"10.4088\/JCP.10m06191","volume":"72","author":"NA Khin","year":"2011","unstructured":"Khin NA, Chen YF, Yang Y, Yang P, Laughren TP. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry. 2011;72:464\u201372.","journal-title":"J Clin Psychiatry"},{"key":"284_CR36","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357\u201366.","journal-title":"Lancet"},{"key":"284_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.4088\/JCP.14m09619","volume":"77","author":"SG Ball","year":"2016","unstructured":"Ball SG, Ferguson MB, Martinez JM, Pangallo BA, Nery ES, Dellva MA, et al. Efficacy outcomes from 3 clinical trials of edivoxetine as adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment. J Clin Psychiatry. 2016;77:635\u201342.","journal-title":"J Clin Psychiatry"},{"key":"284_CR38","doi-asserted-by":"crossref","unstructured":"Hobart M, Skuban A, Zhang P, Josiassen MK, Hefting N, Augustine C et al. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study. Curr Med Res Opin. 2018;34:633\u201342.","DOI":"10.1080\/03007995.2018.1430220"},{"key":"284_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3109\/15622975.2014.989261","volume":"16","author":"HJ M\u00f6ller","year":"2015","unstructured":"M\u00f6ller HJ, Demyttenaere K, Olausson B, Szamosi J, Wilson E, Hosford D, et al. Two phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. World J Biol Psychiatry. 2015;16:483\u2013501.","journal-title":"World J Biol Psychiatry"},{"key":"284_CR40","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.4088\/JCP.14m09688","volume":"76","author":"ME Thase","year":"2015","unstructured":"Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, et al. Efficacy and safety of adjunctive brexpiprazole 2\u2009mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76:1224\u201331.","journal-title":"J Clin Psychiatry"},{"key":"284_CR41","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.4088\/JCP.14m09689","volume":"76","author":"ME Thase","year":"2015","unstructured":"Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76:1232\u201340.","journal-title":"J Clin Psychiatry"},{"key":"284_CR42","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.euroneuro.2013.12.008","volume":"24","author":"E Vieta","year":"2014","unstructured":"Vieta E, Thase ME, Naber D, D\u2019Souza B, Rancans E, Lepola U, et al. Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant. Eur Neuropsychopharmacol. 2014;24:564\u201374.","journal-title":"Eur Neuropsychopharmacol"},{"key":"284_CR43","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1185\/03007995.2015.1037732","volume":"31","author":"TM Oakes","year":"2015","unstructured":"Oakes TM, Dellva MA, Waterman K, Greenbaum M, Poppe C, Goldberger C, et al. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder. Curr Med Res Opin. 2015;31:1179\u201389.","journal-title":"Curr Med Res Opin"},{"key":"284_CR44","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.brs.2017.09.010","volume":"11","author":"M Fava","year":"2018","unstructured":"Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, et al. Double-blind, proof-of-concept (POC) trial of low-field magnetic stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimul. 2018;11:75\u201384.","journal-title":"Brain Stimul"},{"key":"284_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000332050","volume":"81","author":"M Fava","year":"2012","unstructured":"Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom. 2012;81:87\u201397.","journal-title":"Psychother Psychosom"},{"key":"284_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000069738","volume":"72","author":"M Fava","year":"2003","unstructured":"Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72:115\u201327.","journal-title":"Psychother Psychosom"},{"key":"284_CR47","doi-asserted-by":"publisher","unstructured":"Patel KV, Allen R, Burke L, Farrar JT, Gewandter JS, Gilron I et al. Evaluation of composite responder outcomes of pain intensity and physical function in neuropathic pain clinical trials: an ACTTION individual patient data analysis.\u00a0Pain. 2018 \n                  https:\/\/doi.org\/10.1097\/j.pain.0000000000001324\n                  \n                .","DOI":"10.1097\/j.pain.0000000000001324"},{"key":"284_CR48","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00213-007-0975-9","volume":"196","author":"S Weinmann","year":"2008","unstructured":"Weinmann S, Becker T, Koesters M. Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis. Psychopharmacology (Berl). 2008;196:511\u201320.","journal-title":"Psychopharmacology"},{"key":"284_CR49","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/adb.12163","volume":"20","author":"JD Jones","year":"2015","unstructured":"Jones JD, Sullivan MA, Vosburg SK, Manubay JM, Mogali S, Metz V, et al. Abuse potential of intranasal buprenorphine versus buprenorphine\/naloxone in buprenorphine-maintained heroin users. Addict Biol. 2015;20:784\u201398.","journal-title":"Addict Biol"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41380-018-0284-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-018-0284-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41380-018-0284-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T16:59:23Z","timestamp":1684601963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-018-0284-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["284"],"URL":"https:\/\/doi.org\/10.1038\/s41380-018-0284-1","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,29]]},"assertion":[{"value":"30 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MF reports 3-year disclosures below, and all lifetime disclosures can be viewed online at:\n                      \n                      ; research support: Alkermes, Inc., Johnson & Johnson, Axsome, Acadia Pharmaceuticals, Cerecor, Lundbeck Inc., Neuralstem, Otsuka, Taisho, Marinus Pharmaceuticals, BioHaven, Takeda, Vistagen, Relmada Therapeutics Inc., Stanley Medical Research Institute (SMRI), National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH), and PCORI. Dr. Fava has not done any personal consulting. Any consulting he has done has been on behalf of Massachusetts General Hospital. Stock\/Other Financial Options: Equity Holdings: Compellis; PsyBrain, Inc. Royalty\/patent, other income: patents for Sequential Parallel Comparison Design (SPCD) (US_7840419, US_7647235, US_7983936, US_8145504, US_8145505); and patent application for a combination of Ketamine plus Scopolamine in Major Depressive Disorder (MDD), licensed by MGH to Biohaven. Patents for pharmacogenomics of Depression Treatment with Folate (US_9546401, US_9540691). Copyright for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), Symptoms of Depression Questionnaire (SDQ), and SAFER; Lippincott, Williams & Wilkins; Wolkers Kluwer; World Scientific Publishing Co. Pte. Ltd. MET has served as an advisor or consultant to Acadia, Akilii, Alkermes, Allergan (includes Forest Laboratories and Naurex), AstraZeneca, Cerecor, Eli Lilly, Fabre-Kramer, Gerson Lehrman Group, Guidepoint Global, Johnson & Johnson Pharmaceutical Research & Development LLC (Janssen, Ortho-McNeil), Lundbeck, MedAvante, Merck, Moskha8, Nestl\u00e9 (PamLab), Novartis, Otsuka, Pfizer, Shire, Sunovion, and Takeda; he has received grant support from Acadia, Agency for Healthcare Research and Quality, Alkermes, Avanir, Forest, Intracellular, Janssen, National Institute of Mental Health, Otsuka, Patient Centered Outcomes Research Institute, and Takeda; he has received royalties from American Psychiatric Press, Guilford Publications, Herald House, and WW Norton & Company Inc.; his spouse is employed by Peloton Advantage, which does business with a number of pharmaceutical companies. MHT has served as an advisor or consultant to AcademyHealth, Alkermes Inc., Akili Interactive, Allergan Pharmaceuticals, ACADIA Pharmaceuticals Inc., American Society of Clinical Psychopharmacology, Brain Institute Canada (CAN-BIND), Brintellix Global, Global Medical Education, Healthcare Global Village, Health Research Associates, Jazz Pharmaceuticals, Lundbeck Research USA, Medscape LLC, MSI Methylation Sciences Inc., Nestle Health Science\u2014Pamlab Inc., Naurex Inc., Navitor, One Carbon Therapeutics, Otsuka America Pharmaceutical Inc., Saatchi, and Takeda Global Research; he has received grant support from National Institute of Mental Health, National Institute on Drug Abuse, Johnson & Johnson Pharmaceutical Research & Development LLC, and Janssen Research and Development LLC; he has received royalties from Janssen Research and Development LLC; he has publications for Janssen Asia Pacific and Oxford University Press. EE, WFM, AM, NN, ADS, MY, and SP are employees and stockholders of Alkermes, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}